Lynne A. Bui

960 total citations
21 papers, 503 citations indexed

About

Lynne A. Bui is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Lynne A. Bui has authored 21 papers receiving a total of 503 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Lynne A. Bui's work include Cancer Treatment and Pharmacology (5 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (4 papers). Lynne A. Bui is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Cancer Research and Treatments (4 papers) and CAR-T cell therapy research (4 papers). Lynne A. Bui collaborates with scholars based in United States, India and Spain. Lynne A. Bui's co-authors include Douglas O. Clary, Neil P. Shah, Lisa H. Butterfield, Antoni Ribas, John A. Glaspy, William H. McBride, James S. Economou, Roy Lau, Lubomir Sokol and Jörge E. Cortes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lynne A. Bui

20 papers receiving 487 citations

Peers

Lynne A. Bui
Marianne Rissler Sweden
Emmanuel J. Volanakis United States
J. W. G. Janssen Germany
Z. Zu United States
Hans G. Drexler Germany
Lars Klemm United States
Anna Kreutzman Finland
Helen M. Pomykala United States
CJ Eaves Canada
Marina Lafage France
Marianne Rissler Sweden
Lynne A. Bui
Citations per year, relative to Lynne A. Bui Lynne A. Bui (= 1×) peers Marianne Rissler

Countries citing papers authored by Lynne A. Bui

Since Specialization
Citations

This map shows the geographic impact of Lynne A. Bui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynne A. Bui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynne A. Bui more than expected).

Fields of papers citing papers by Lynne A. Bui

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lynne A. Bui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynne A. Bui. The network helps show where Lynne A. Bui may publish in the future.

Co-authorship network of co-authors of Lynne A. Bui

This figure shows the co-authorship network connecting the top 25 collaborators of Lynne A. Bui. A scholar is included among the top collaborators of Lynne A. Bui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynne A. Bui. Lynne A. Bui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kundranda, Madappa N., Can Bruce, Elder Granger, et al.. (2024). Predictive multi-omics analysis of BPM31510 in combination with gemcitabine in a phase 2 study of advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 42(3_suppl). 696–696. 1 indexed citations
2.
Hundt, Matthias, Peter F. Bove, Michelle Li, et al.. (2021). 774 An induced pluripotent stem cell (iPSC) vaccine is highly immunogenic and reduces lung metastases in a mouse model of melanoma. SHILAP Revista de lepidopterología. A809–A809. 1 indexed citations
3.
4.
Hundt, Matthias, Michelle Li, Carlos A. Obejero‐Paz, et al.. (2021). 775 An induced pluripotent stem cell (iPSC) vaccine decreases tumor growth and improves survival in a therapeutic mouse model of colon cancer. SHILAP Revista de lepidopterología. A810–A810. 1 indexed citations
5.
Kundranda, Madappa N., David Propper, Paul S. Ritch, et al.. (2020). Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC).. Journal of Clinical Oncology. 38(4_suppl). 723–723. 2 indexed citations
6.
Bui, Lynne A., Susan Hurst, Gregory L. Finch, et al.. (2015). Key considerations in the preclinical development of biosimilars. Drug Discovery Today. 20. 3–15. 46 indexed citations
7.
Wee, Wen, Jennifer R. Diamond, Grace K. Dy, et al.. (2014). A phase I and pharmacokinetic study of a weekly dosing schedule of paclitaxel injection concentrate for nano-dispersion (PICN) in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2566–2566.
8.
Verstovšek, Srđan, Constantine S. Tam, Martha Wadleigh, et al.. (2013). Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. Leukemia Research. 38(3). 316–322. 37 indexed citations
9.
Bui, Lynne A. & Carrie Turich Taylor. (2013). Developing Clinical Trials for Biosimilars. Seminars in Oncology. 41. S15–S25. 16 indexed citations
10.
Wee, Wen, Elaine T. Lam, Grace K. Dy, et al.. (2013). A pharmacokinetic and dose-escalating study of paclitaxel injection concentrate for nano-dispersion (PICN) alone and with carboplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2557–2557. 3 indexed citations
11.
Infante, Jeffrey R., Josep Tabernero, Howard A. Burris, et al.. (2012). Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies. Cancer Research. 72(8_Supplement). 5588–5588. 7 indexed citations
12.
Winer, Jeffery A., et al.. (2010). GABAergic organization of the auditory cortex in the mustached bat (Pteronotus p. parnellii). Hearing Research. 274(1-2). 105–120. 3 indexed citations
13.
Papadopoulos, Kyriakos P., David S. Siegel, Seema Singhal, et al.. (2010). Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 116(21). 3024–3024. 5 indexed citations
14.
15.
Shah, Neil P., Lubomir Sokol, Srđan Verstovšek, et al.. (2008). A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. Blood. 112(11). 98–98. 51 indexed citations
16.
Paquette, Ronald, Lubomir Sokol, Neil P. Shah, et al.. (2008). A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. Blood. 112(11). 2810–2810. 27 indexed citations
17.
Verstovšek, Srđan, Animesh Pardanani, Neil P. Shah, et al.. (2007). A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis.. Blood. 110(11). 553–553. 31 indexed citations
18.
Shah, Neil P., Corynn Kasap, Ronald Paquette, et al.. (2007). Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.. Blood. 110(11). 474–474. 18 indexed citations
19.
Butterfield, Lisa H., Nitya G. Chakraborty, Lynne A. Bui, et al.. (1998). Generation of Melanoma-Specific Cytotoxic T Lymphocytes by Dendritic Cells Transduced with a MART-1 Adenovirus. The Journal of Immunology. 161(10). 5607–5613. 132 indexed citations
20.
Bui, Lynne A., Lisa H. Butterfield, Antoni Ribas, et al.. (1997). In Vivo Therapy of Hepatocellular Carcinoma with a Tumor-Specific Adenoviral Vector Expressing Interleukin-2. Human Gene Therapy. 8(18). 2173–2182. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marianne Rissler Breakdown of academic impact, for papers by Emmanuel J. Volanakis Breakdown of academic impact, for papers by J. W. G. Janssen Breakdown of academic impact, for papers by Z. Zu Breakdown of academic impact, for papers by Hans G. Drexler Breakdown of academic impact, for papers by Lars Klemm Breakdown of academic impact, for papers by Anna Kreutzman Breakdown of academic impact, for papers by Helen M. Pomykala Breakdown of academic impact, for papers by CJ Eaves Breakdown of academic impact, for papers by Marina Lafage
Rankless by CCL
2026